21:59 , Jan 2, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice with myeloid-specific BIM knockout could be used to screen for lupus therapies. In mice, myeloid cell-specific knockout of BIM produced levels of serum antinuclear autoantibodies and recapitulated the splenomegaly and glomerulonephritis-related...
08:00 , Feb 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: BCL2-like 11 apoptosis facilitator (BCL2L11; BIM); epidermal growth factor receptor (EGFR)

Cancer INDICATION: Brain cancer In vitro studies suggest BIM mimetics or MEK inhibitors could help treat EGFR inhibitor-resistant glioblastoma multiforme (GBM). In patient-derived GBM cells treated with an EGFR inhibitor, resistant cells exhibited higher activity of the...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Clinical News

PraediCare Dx: Data

An analysis of peripheral blood mononuclear cells (PBMCs) or bone marrow aspirates from 62 newly diagnosed AML patients showed that Eutropic's PraediCare Dx test predicted patient response to cytarabine-based treatment regimens with 90% accuracy. Additionally,...
07:00 , Jun 28, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) BCL2-like 11 apoptosis facilitator (BCL2L11; BIM) A study...
07:00 , Apr 12, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) B cell lymphoma 2 (BCL-2; BCL2); BCL2-like 11 apoptosis facilitator (BCL2L11; BIM) ...
07:00 , Apr 12, 2012 |  BC Innovations  |  Cover Story

Targeting CDK in triple-negative breast cancer

A team at the University of California, San Francisco has found a dysregulated MYC pathway that underlies the majority of triple-negative breast cancers-a form of the disease with limited treatment options.1 The researchers also showed...
07:00 , Apr 5, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Intronic deletions in BCL2-like 11 apoptosis facilitator (BCL2L11; BIM) as a marker for tyrosine kinase inhibitor drug resistance and...
07:00 , Sep 8, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers BCL2-like 11 apoptosis facilitator (BCL2L11; BIM) expression as a predictor of cancer response to kinase inhibitor therapy Cell culture...
07:00 , Oct 30, 2008 |  BC Innovations  |  Cover Story

BCL-2 double take

Researchers at the Burnham Institute for Medical Research and the Dana-Farber Cancer Institute have independently identified peptides that modulate mitochondrial apoptosis and may have promise in cancer. The therapeutic strategies are, however, quite different: in...
07:00 , Oct 30, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer ...